The good, the bad and lots of just plain old ug­ly: The Q1 num­bers are in

Any­one ex­pect­ing much up­beat news for biotech in Q1 of this year was in for a sore dis­ap­point­ment.

Our num­bers czar, Deal­For­ma’s Chris Doko­ma­ji­lar, crunched …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER